The pharma major Sun Pharma has entered into an agreement with Israel’s Weizmann Institute of Science and Spain’s Health Research Institute of Santiago de Compostela for developing products for the treatment of neurological diseases like brain stroke and glioblastoma, a lethal brain cancer.

The company said in a statement that “As per the signed tripartite agreement, Sun Pharma will have the first right to develop these additional indications”.

It further added that Sun Pharma will have the exclusive options to conduct further development of the enzyme after completion of the pre-clinical studies.

Read EquityPandit’s Nifty Pharma Outlook for this week